Atridia
CompanyAustralia
Atridia develops 2 assets, the furthest in phase 3 (HRS-1893 in obstructive hypertrophic cardiomyopathy (oHCM)). Mostly small molecule and peptide; based in Australia.
- 2
- Assets
- Furthest stage
- Phase 3
- 3
- Trials
- 1
- Signal
Pipeline
2Inhibits cardiac myosin to reduce excessive heart muscle contraction.
Phase 3, Small molecule, obstructive hypertrophic cardiomyopathy (oHCM), hypertrophic cardiomyopathy (Phase 2)
Investigational therapy for obesity
Phase 1, Peptide, obesity, overweight
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials3
- Signals5
- Similar companies6